Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWOG S0012: Neoadjuvant Chemotherapy in Breast Cancer
NCT00016406Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2001
- Primary completion
- Sep 2006
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim in inflammatory breast cancer (IBC) and breast cancer (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Microscopic Pathologic Response Rate. Started May 2001; status: completed.
02
Drugs
filgrastim
03
Conditions
inflammatory breast cancer (IBC)breast cancer
Beyond the preview
Go deeper on NCT00016406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016406.